Charles River Laboratories International, Inc.
CRL
$138.79
-$2.57-1.82%
NYSE
| 03/29/2025 | 12/28/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -1.83% | -0.71% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.83% | -0.71% | |||
| Cost of Revenue | -6.49% | 7.29% | |||
| Gross Profit | 8.39% | -14.68% | |||
| SG&A Expenses | -9.32% | 3.97% | |||
| Depreciation & Amortization | -27.80% | 27.22% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.03% | 7.32% | |||
| Operating Income | 71.54% | -47.34% | |||
| Income Before Tax | 116.60% | -337.60% | |||
| Income Tax Expenses | 431.80% | -114.53% | |||
| Earnings from Continuing Operations | 112.11% | -404.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 45.32% | -17.24% | |||
| Net Income | 111.87% | -407.93% | |||
| EBIT | 71.54% | -47.34% | |||
| EBITDA | 28.13% | -27.78% | |||
| EPS Basic | 111.92% | -415.65% | |||
| Normalized Basic EPS | 185.52% | -72.25% | |||
| EPS Diluted | 111.85% | -417.14% | |||
| Normalized Diluted EPS | 184.54% | -72.15% | |||
| Average Basic Shares Outstanding | -0.90% | -0.50% | |||
| Average Diluted Shares Outstanding | -0.56% | -0.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||